Anticoagulation in Pregnancy — 50 Advanced FAQs (SS / DM Level)

Each FAQ is answered with 5 high‑yield, exam‑oriented points, aligned with ESC, ACC/AHA, RCOG, ACOG, and ASH guidance.

---

1. Why is LMWH preferred over UFH in pregnancy?

1. More predictable pharmacokinetics
2. Lower risk of HIT
3. Lower osteoporosis risk
4. Once or twice daily dosing
5. No placental transfer

2. Why are DOACs contraindicated in pregnancy?

1. Placental transfer documented
2. Fetal bleeding risk
3. Lack of randomized safety data
4. Animal teratogenicity signals
5. Unreliable reversal in pregnancy

3. What defines warfarin embryopathy?

1. Nasal hypoplasia
2. Stippled epiphyses
3. Limb hypoplasia
4. Growth restriction
5. CNS abnormalities

4. What is the critical teratogenic window for warfarin?

1. 6–12 weeks gestation
2. Period of organogenesis
3. Dose‑dependent risk
4. Higher risk >5 mg/day
5. Irreversible fetal effects

5. Indications for therapeutic LMWH in pregnancy?

1. Acute VTE
2. Recurrent prior VTE
3. Mechanical heart valves
4. LV thrombus
5. APS with thrombosis

6. Target anti‑Xa levels for LMWH?

1. Prophylactic: 0.2–0.6 IU/mL
2. Therapeutic: 0.8–1.2 IU/mL
3. Mechanical valve: 1.0–1.2 IU/mL
4. Sample at 4 hours post‑dose
5. Adjust for weight changes

7. When is anti‑Xa monitoring mandatory?

1. Mechanical heart valves
2. Extremes of body weight
3. Renal dysfunction
4. Recurrent thrombosis
5. Breakthrough events

8. Why is postpartum period highest risk for VTE?

1. Hypercoagulable rebound
2. Venous stasis
3. Endothelial injury
4. Reduced mobility
5. Prothrombotic hormonal milieu

9. Minimum duration of anticoagulation after pregnancy‑associated VTE?

1. At least 3 months total
2. Mandatory 6 weeks postpartum
3. Extend if ongoing risk
4. Independent of delivery mode
5. Not symptom‑based

10. Management of APS in pregnancy?

1. Therapeutic or prophylactic LMWH
2. Low‑dose aspirin
3. Avoid warfarin antepartum
4. Intensify postpartum
5. Multidisciplinary care

11. Differences between inherited and acquired thrombophilia in pregnancy?

1. APS is acquired
2. APS higher obstetric risk
3. Inherited forms vary in penetrance
4. APS requires aspirin
5. Testing affects management

12. High‑risk inherited thrombophilias?

1. Antithrombin deficiency
2. Homozygous FVL
3. Homozygous prothrombin mutation
4. Combined defects
5. Prior VTE association

13. Low‑risk thrombophilias?

1. Heterozygous FVL
2. Heterozygous prothrombin mutation
3. Isolated protein C deficiency
4. No prior VTE
5. Usually postpartum prophylaxis only

14. Indications for antepartum prophylaxis after prior VTE?

1. Unprovoked VTE
2. Estrogen‑related VTE
3. Multiple prior events
4. Persistent risk factors
5. Thrombophilia overlap

15. When is postpartum‑only prophylaxis sufficient?

1. Single provoked VTE
2. Major transient risk factor
3. No thrombophilia
4. No family history
5. Rapid mobilization

16. Peripartum LMWH discontinuation rules?

1. 24 h before planned delivery
2. 24 h before neuraxial block
3. Earlier if renal impairment
4. Switch to UFH if high risk
5. Document last dose

17. Why is UFH preferred near delivery?

1. Short half‑life
2. Complete reversibility
3. IV titratability
4. Safe with neuraxial planning
5. Rapid postpartum restart

18. Restarting anticoagulation postpartum — principles?

1. Ensure hemostasis
2. 6–12 h after vaginal delivery
3. 12–24 h after C‑section
4. High‑risk patients earlier
5. Continue ≥6 weeks

19. Breastfeeding and anticoagulants — key points?

1. LMWH safe
2. UFH safe
3. Warfarin safe
4. DOACs not recommended
5. No dose adjustment needed

20. Mechanical heart valves — why are they high risk in pregnancy?

1. Hypercoagulable state
2. Increased valve thrombosis
3. Limited drug options
4. Hemodynamic stress
5. High maternal mortality

21. Mechanical mitral vs aortic valves — difference?

1. Mitral higher thrombosis risk
2. Lower flow velocities
3. Larger thrombogenic surface
4. More embolic events
5. Aggressive anticoagulation needed

22. LMWH‑only strategy in mechanical valves — limitations?

1. Higher thrombosis rates
2. Requires strict monitoring
3. Dose escalation common
4. Breakthrough events reported
5. Not suitable for all valves

23. Warfarin‑based strategy in mechanical valves — advantages?

1. Best maternal protection
2. Stable INR monitoring
3. Lower valve thrombosis
4. Familiar management
5. Predictable efficacy

24. Criteria allowing cautious warfarin use in pregnancy?

1. Dose ≤5 mg/day
2. Informed consent
3. High maternal risk
4. Second trimester use
5. Specialist supervision

25. Switching strategies across trimesters — rationale?

1. Avoid first‑trimester teratogenicity
2. Optimize maternal safety later
3. Balance fetal–maternal risk
4. Timing with organogenesis
5. Delivery planning

26. Role of aspirin in pregnancy anticoagulation?

1. APS management
2. Preeclampsia prevention
3. Adjunct, not monotherapy
4. Low‑dose only
5. Minimal bleeding risk

27. Why is fondaparinux rarely used?

1. Limited pregnancy data
2. Possible placental passage
3. Long half‑life
4. No reversal agent
5. Reserved for HIT

28. Heparin‑induced thrombocytopenia in pregnancy — approach?

1. Stop all heparins
2. Use fondaparinux or argatroban
3. Avoid warfarin initially
4. Platelet recovery first
5. Specialist care

29. Renal dysfunction and anticoagulation choice?

1. Avoid LMWH accumulation
2. Prefer UFH
3. Monitor aPTT
4. Adjust postpartum
5. Higher bleeding vigilance

30. Obesity and LMWH dosing challenges?

1. Weight‑based dosing mandatory
2. Anti‑Xa monitoring required
3. Dose escalation common
4. Under‑dosing risk
5. Dynamic weight changes

31. Under‑anticoagulation consequences in pregnancy?

1. Recurrent VTE
2. Valve thrombosis
3. Maternal mortality
4. Fetal loss
5. Emergency interventions

32. Over‑anticoagulation risks in pregnancy?

1. Maternal bleeding
2. Placental abruption
3. Postpartum hemorrhage
4. Spinal hematoma
5. Surgical complications

33. Anticoagulation in cardiomyopathy with LV thrombus?

1. LMWH preferred
2. Avoid DOACs
3. Continue through pregnancy
4. Postpartum transition possible
5. Imaging‑guided duration

34. AF in pregnancy — anticoagulation principles?

1. CHA₂DS₂‑VASc applies
2. LMWH if indicated
3. Rate control prioritized
4. Rhythm strategy individualized
5. Avoid DOACs

35. Pregnancy‑related physiological changes affecting anticoagulation?

1. Increased plasma volume
2. Increased renal clearance
3. Reduced protein binding
4. Hypercoagulability
5. Weight gain

36. Why is INR unreliable in pregnancy for non‑warfarin drugs?

1. INR measures vitamin K antagonism
2. Heparins do not affect INR
3. Physiological INR variation
4. Misleading safety signal
5. Anti‑Xa preferred

37. Role of multidisciplinary team (MDT)?

1. Cardiology input
2. Obstetric planning
3. Hematology dosing
4. Anesthesia coordination
5. Neonatal preparedness

38. Common exam trap regarding anticoagulation in pregnancy?

1. Choosing DOACs
2. Forgetting postpartum period
3. Missing neuraxial timing
4. Ignoring mechanical valve risk
5. Underestimating APS

39. Why is aspirin alone insufficient for VTE prevention?

1. Venous clots are fibrin‑rich
2. Platelet role limited
3. Inadequate efficacy
4. No dose escalation benefit
5. Only adjunctive role

40. Anticoagulation differences between vaginal and cesarean delivery?

1. Higher bleeding with C‑section
2. Delayed restart in surgery
3. Same total duration
4. Individual hemostasis assessment
5. Thrombosis risk persists

41. Why should anticoagulation never be stopped prematurely postpartum?

1. Sustained hypercoagulability
2. Hormonal withdrawal
3. Reduced mobility
4. Surgical wounds
5. High PE mortality

42. Imaging follow‑up for pregnancy‑associated VTE?

1. Symptom‑guided
2. Avoid radiation when possible
3. Ultrasound preferred
4. CT only if essential
5. Does not shorten therapy

43. Interaction of preeclampsia and thrombosis risk?

1. Endothelial dysfunction
2. Increased platelet activation
3. Higher VTE incidence
4. Aspirin benefit
5. Careful bleeding balance

44. Why are bioprosthetic valves preferred in women planning pregnancy?

1. No lifelong anticoagulation
2. Lower pregnancy risk
3. Easier peripartum care
4. Reduced fetal exposure
5. Acceptable durability

45. Management of breakthrough thrombosis on LMWH?

1. Confirm compliance
2. Check anti‑Xa levels
3. Increase dose
4. Switch strategy if needed
5. MDT review

46. Key counseling points before pregnancy in anticoagulated women?

1. Maternal risk discussion
2. Fetal risk explanation
3. Drug switching plan
4. Monitoring frequency
5. Delivery strategy

47. Why is pregnancy considered a hypercoagulable state?

1. Increased clotting factors
2. Reduced protein S
3. Venous stasis
4. Placental thromboplastin
5. Evolutionary hemorrhage protection

48. Anticoagulation in assisted reproductive techniques?

1. Estrogen increases VTE risk
2. Consider prophylactic LMWH
3. APS screening important
4. Early pregnancy vigilance
5. Individual risk assessment

49. Common reasons for anticoagulation failure in pregnancy?

1. Under‑dosing
2. Weight changes
3. Missed doses
4. Lack of monitoring
5. Delayed escalation

50. Single best exam mantra for anticoagulation in pregnancy?

1. LMWH is default
2. DOACs are wrong
3. Postpartum period is critical
4. Mechanical valves are highest risk
5. MDT care saves lives

concise, guideline-concordant summary of anticoagulation in pregnancy, aligned with major society recommendations (ESC, ACC/AHA, RCOG, ACOG, ASH).

---

1. Core Principles

• Placental transfer
  • Does NOT cross placenta: Unfractionated heparin (UFH), Low-molecular-weight heparin (LMWH)
  • Crosses placenta (teratogenic/fetotoxic): Warfarin, DOACs → contraindicated
• Preferred agents in pregnancy: LMWH > UFH
• Monitoring: Anti-Xa monitoring in selected high-risk situations

---

2. Anticoagulants: What to Use and Avoid

Recommended

Drug	Use in Pregnancy
LMWH (Enoxaparin, Dalteparin)	First-line for prophylaxis & treatment
UFH	Alternative when rapid reversal needed (near delivery, renal failure)

Contraindicated

Drug	Reason
Warfarin	Embryopathy (6–12 weeks), fetal bleeding
DOACs (Apixaban, Rivaroxaban, Dabigatran)	Placental transfer, insufficient safety data
Fondaparinux	Limited data; reserve only if HIT with no alternative

---

3. Indication-Specific Recommendations

A. Venous Thromboembolism (VTE)

Acute VTE in Pregnancy

• LMWH (therapeutic dose) throughout pregnancy
• Continue minimum 3 months AND at least 6 weeks postpartum

Typical dosing

• Enoxaparin: 1 mg/kg SC twice daily or 1.5 mg/kg once daily

Previous VTE (Secondary Prophylaxis)

Risk Category	Recommendation
Unprovoked / estrogen-related VTE	Prophylactic or intermediate-dose LMWH
Provoked VTE (transient risk)	Postpartum LMWH (6 weeks)
Multiple prior VTE	Therapeutic-dose LMWH

---

B. Thrombophilia

Condition	Anticoagulation
Antiphospholipid syndrome (APS)	LMWH + low-dose aspirin
High-risk inherited thrombophilia + prior VTE	LMWH antepartum + postpartum
Low-risk thrombophilia, no VTE	Usually postpartum only

---

C. Mechanical Heart Valves (High-Risk Group)

Options (none ideal; individualize):

1. Adjusted-dose LMWH throughout pregnancy (anti-Xa 0.8–1.2 IU/mL)
2. LMWH (1st trimester) → Warfarin (2nd–early 3rd trimester) → LMWH
   • Consider warfarin only if dose ≤5 mg/day
3. UFH IV (less effective, higher thrombosis risk)

Management requires multidisciplinary care (cardiology–obstetrics–hematology).

---

D. Atrial Fibrillation / Other Cardiac Indications

• LMWH if anticoagulation required
• DOACs contraindicated
• Warfarin avoided except rare, specialist-guided situations

---

4. Dosing and Monitoring

LMWH Monitoring

• Not routine
• Check anti-Xa (4 hours post-dose) if:
  • Mechanical valves
  • Extreme body weight
  • Renal dysfunction
  • Recurrent thrombosis

Target Anti-Xa

• Prophylactic: 0.2–0.6 IU/mL
• Therapeutic: 0.8–1.2 IU/mL

---

5. Peripartum Management

Situation	Recommendation
Planned delivery	Stop LMWH 24 h before
Neuraxial anesthesia	≥12 h (prophylactic) / ≥24 h (therapeutic)
High thrombotic risk	Switch to IV UFH near term
Post-delivery restart	6–12 h (vaginal), 12–24 h (C-section)

---

6. Postpartum Anticoagulation

• Highest VTE risk period
• Continue anticoagulation for ≥6 weeks
• Warfarin safe in breastfeeding
• LMWH safe in breastfeeding
• DOACs not recommended during breastfeeding

---

7. Key Take-Home Messages

• LMWH is the anticoagulant of choice in pregnancy
• Warfarin and DOACs are contraindicated
• Mechanical valves = highest risk → individualized strategy
• Postpartum period requires mandatory protection

---

Pregnant patient → Need for anticoagulation?

⬇️

Step 1: Indication

• Acute VTE
• Prior VTE
• Thrombophilia
• Mechanical valve
• AF / cardiomyopathy

⬇️

Step 2: Drug Selection

• LMWH → First-line
• UFH → If near delivery / renal failure
• ❌ Warfarin / DOACs → Avoid

⬇️

Step 3: Dose Strategy

• Prophylactic / Intermediate / Therapeutic
• Weight-based dosing
• Anti-Xa monitoring if high risk

⬇️

Step 4: Peripartum Planning

• Stop LMWH 24 h pre-delivery
• Consider UFH switch if very high risk
• Neuraxial timing respected

⬇️

Step 5: Postpartum

• Restart anticoagulation early
• Continue ≥6 weeks
• Warfarin or LMWH acceptable during breastfeeding

---

II. DRUG SELECTION TABLE (CORE GUIDELINES)

Drug	Placenta	Use in Pregnancy
LMWH	❌	First-line
UFH	❌	Alternative
Warfarin	✅	Contraindicated (except selected valve cases)
DOACs	✅	Contraindicated
Fondaparinux	Minimal	Only if HIT

---

III. LMWH DOSING TABLE (WEIGHT-BASED)

Therapeutic Anticoagulation

Drug	Dose
Enoxaparin	1 mg/kg SC 12-hourly
Dalteparin	100 IU/kg 12-hourly

Prophylactic Anticoagulation

Weight	Enoxaparin
<50 kg	20 mg OD
50–90 kg	40 mg OD
91–130 kg	60 mg OD
>130 kg	80 mg OD

---

IV. ANTI-Xa MONITORING (ADVANCED POINT)

Situation	Target Anti-Xa (4 h post-dose)
Prophylactic	0.2–0.6 IU/mL
Therapeutic	0.8–1.2 IU/mL
Mechanical valve	1.0–1.2 IU/mL

Indications for monitoring

• Mechanical valves
• Extremes of body weight
• Renal dysfunction
• Recurrent thrombosis

---

V. INDICATION-WISE GUIDELINES

A. Acute VTE in Pregnancy

• Therapeutic LMWH throughout pregnancy
• Minimum 3 months total
• ≥6 weeks postpartum mandatory

---

B. Previous VTE

Risk Profile	Strategy
Unprovoked / estrogen-related	Antepartum + postpartum LMWH
Provoked (transient risk)	Postpartum LMWH only
Multiple VTE	Therapeutic LMWH

---

C. Thrombophilia

Condition	Management
APS	LMWH + low-dose aspirin
High-risk inherited thrombophilia + VTE	Antepartum + postpartum LMWH
Low-risk, no VTE	Usually postpartum only

---

D. Mechanical Heart Valves (MOST EXAMINED)

Accepted Strategies

Strategy	Pros	Cons
LMWH throughout	Fetal safety	Valve thrombosis risk
LMWH → Warfarin → LMWH	Best efficacy	Teratogenicity
UFH	Reversible	Inferior protection

Warfarin may be considered ONLY if dose ≤5 mg/day and after shared decision-making.

---

E. AF / Cardiomyopathy

• LMWH if CHA₂DS₂-VASc warrants anticoagulation
• DOACs contraindicated
• Warfarin avoided unless specialist-guided

---

VI. PERIPARTUM ANTICOAGULATION TABLE

Scenario	Recommendation
Planned delivery	Stop LMWH 24 h before
Neuraxial anesthesia	≥12 h (prophylactic), ≥24 h (therapeutic)
Very high thrombotic risk	Switch to IV UFH
Restart after delivery	6–12 h (vaginal), 12–24 h (C-section)

---

VII. POSTPARTUM & BREASTFEEDING

Drug	Breastfeeding
LMWH	Safe
UFH	Safe
Warfarin	Safe
DOACs	Not recommended

Postpartum anticoagulation = ≥6 weeks (highest VTE risk period).

---

VIII. MECHANICAL VALVE PREGNANCY DECISION MATRIX (HIGH-YIELD)

Valve Type	Preferred Strategy
Mitral mechanical	Warfarin-based strategy preferred
Aortic bileaflet	LMWH possible with strict monitoring
Prior valve thrombosis	Avoid LMWH-only strategy

---